Commentary Challenges Claims of Exceptional Melflufen Responses in Multiple Myeloma
A new commentary argues that exceptional long-term responses to melflufen-dexamethasone in myeloma case reports should not override subgroup trial evidence ...
A new commentary argues that exceptional long-term responses to melflufen-dexamethasone in myeloma case reports should not override subgroup trial evidence ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine